Publications by authors named "Monica Rizzetto"
Article Synopsis
- Cemiplimab, an antibody targeting the PD-1 receptor, is being evaluated in a real-world study in Italy for patients with advanced cervical cancer who have undergone platinum-based chemotherapy, following promising initial trial results.
- The study involved 135 patients, assessing primary outcomes like progression-free survival (PFS) and overall survival (OS), along with safety and response rates to treatment.
- Results showed a median PFS of 4 months and median OS of 12 months, with anemia and fatigue being the most common side effects, highlighting the treatment's feasibility in clinical practice.
Background: In addition to pharmacological prevention, chemotherapy-induced nausea and vomiting (CINV) can be mitigated through patient education; written supporting materials can be beneficial.
Methods: This is a randomized, controlled trial which randomly assigned patients undergoing first chemotherapy cycle to receive oral information regarding CINV prevention and management (control arm) or oral information plus an informative booklet (experimental arm). Overall, 384 cancer patients fulfilling the following inclusion criteria were enrolled: age ≥18 years; life expectancy ≥6 months; no cognitive impairment; written informed consent.